Biotech News

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Arvinas, Inc. (ARVN)ir.arvinas.com2026-05-12 11:08 ESTCommercial

– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on net sales – NEW HAVEN, Conn., May 12, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc.

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Arvinas, Inc.

Arvinas is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ARVNArvinas, Inc.2026-05-29 16:07:30 EST

Arvinas to Present at Jefferies Global Healthcare Conference

ARVNArvinas, Inc.2026-05-18 10:37:52 EST

Arvinas Employees Give Back During Company-wide Impact Day

ARVNArvinas, Inc.2026-05-12 07:08:35 EST

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

ARVNArvinas, Inc.2026-05-06 10:53:23 EST

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States